PMID- 26861811
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160610
LR  - 20200930
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 7
IP  - 2
DP  - 2016 Jun
TI  - Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: 
      Lessons from ORIGIN and Other Cardiovascular Trials.
PG  - 187-201
LID - 10.1007/s13300-016-0153-3 [doi]
AB  - Dysglycemia results from a deficit in first-phase insulin secretion compounded by 
      increased insulin insensitivity, exposing beta cells to chronic hyperglycemia and 
      excessive glycemic variability. Initiation of intensive insulin therapy at 
      diagnosis of type 2 diabetes mellitus (T2DM) to achieve normoglycemia has been 
      shown to reverse glucotoxicity, resulting in recovery of residual beta-cell 
      function. The United Kingdom Prospective Diabetes Study (UKPDS) 10-year 
      post-trial follow-up reported reductions in cardiovascular outcomes and all-cause 
      mortality in persons with T2DM who initially received intensive glucose control 
      compared with standard therapy. In the cardiovascular outcome trial, outcome 
      reduction with an initial glargine intervention (ORIGIN), a neutral effect on 
      cardiovascular disease was observed in the population comprising prediabetes and 
      T2DM. Worsening of glycemic control was prevented over the 6.7 year treatment 
      period, with few serious hypoglycemic episodes and only moderate weight gain, 
      with a lesser need for dual or triple oral treatment versus standard care. 
      Several other studies have also highlighted the benefits of early insulin 
      initiation as first-line or add-on therapy to metformin. The decision to 
      introduce basal insulin to metformin must, however be individualized based on a 
      risk-benefit analysis. The landmark ORIGIN trial provides many lessons relating 
      to the concept and application of early insulin therapy for the prevention and 
      safe and effective induction and maintenance of glycemic control in type 2 
      diabetes. FUNDING: Sanofi.
FAU - Hanefeld, Markolf
AU  - Hanefeld M
AD  - Study Centre Professor Hanefeld, GWT-TUD GmbH, Dresden, Germany.
FAU - Monnier, Louis
AU  - Monnier L
AD  - Institute of Clinical Research, University Montpellier 1, Montpellier, France.
FAU - Schnell, Oliver
AU  - Schnell O
AD  - Ludwig-Maximilians-University, Munich, Germany.
FAU - Owens, David
AU  - Owens D
AD  - Institute of Life Sciences, Swansea University, Swansea, UK. 
      owensdr@cardiff.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160210
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC4900970
OTO - NOTNLM
OT  - Dysglycemia
OT  - Insulin glargine
OT  - ORIGIN study
OT  - Patient-centered treatment
OT  - beta-Cell function
EDAT- 2016/02/11 06:00
MHDA- 2016/02/11 06:01
PMCR- 2016/02/10
CRDT- 2016/02/11 06:00
PHST- 2015/11/10 00:00 [received]
PHST- 2016/02/11 06:00 [entrez]
PHST- 2016/02/11 06:00 [pubmed]
PHST- 2016/02/11 06:01 [medline]
PHST- 2016/02/10 00:00 [pmc-release]
AID - 10.1007/s13300-016-0153-3 [pii]
AID - 153 [pii]
AID - 10.1007/s13300-016-0153-3 [doi]
PST - ppublish
SO  - Diabetes Ther. 2016 Jun;7(2):187-201. doi: 10.1007/s13300-016-0153-3. Epub 2016 
      Feb 10.